Form 4: Bicara CFO Exercises Options, Sells Shares Under 10b5-1 Plan

Bicara Therapeutics CFO Ivan Hyep exercised stock options and subsequently sold 18,400 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc. (BCAX), engaged in transactions involving the company's common stock.
• On November 21, 2025, Hyep exercised options to acquire 605 shares at $3.7898 per share and immediately sold these 605 shares at $18.15 per share.
• On November 24, 2025, Hyep exercised options to acquire 17,795 shares at $3.7898 per share and subsequently sold these 17,795 shares at a weighted average price of $18.5498 per share, with prices ranging from $18.15 to $18.84.
• All transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
• Following these transactions, Hyep beneficially owns 145,355 shares of common stock directly and 98,184 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider selling shares can sometimes be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling. The significant profit from option exercise is a positive for the executive, reflecting value creation from their compensation.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to new, non-public information.
• The exercise of options demonstrates the executive's engagement with their compensation structure.
• The sale price significantly exceeds the exercise price, indicating a profitable transaction for the CFO.

Negatives

• The sale of shares by a Chief Financial Officer, even under a 10b5-1 plan, could be perceived by some investors as a lack of confidence, although this is mitigated by the pre-planned nature.

Future Outlook

NA

Industry Context

This is an individual insider transaction and does not directly relate to broader industry trends or competitors, other than being a common practice for executive compensation in publicly traded biotech companies.

Stakeholder Impact

• Shareholders: The sale of shares by a CFO could be interpreted in various ways, but the 10b5-1 plan reduces the negative signal. The overall impact is likely minimal given the pre-planned nature.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (option exercise and sale) executed under a pre-arranged 10b5-1 plan. Such transactions are common for executives managing their compensation and liquidity. While a sale by a CFO might warrant attention, the pre-planned nature significantly reduces any negative signaling. The filing itself does not provide new fundamental information about the company's operations, financial health, or strategic direction that would alter an investment thesis. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell the stock.

Keywords

Bicara Therapeutics, BCAX, Ivan Hyep, CFO, Form 4, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, Executive Compensation